Most active New York Stock Exchange-traded stocks
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Shire, ArmaGen Ink Licensing Agreeement for AGT-182 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 5:00PM CDT
Shire (SHPG) recently entered into a worldwide licensing and collaboration agreement with U.S. based privately-held biotechnology company, ArmaGen.
Obama wants limits on US company mergers abroad
AP - Thu Jul 24, 4:32PM CDT
LOS ANGELES (AP) — Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers.
Pfizer's Incoming Patent Cliff
Dan Carroll, The Motley Fool - Motley Fool - Thu Jul 24, 4:00PM CDT
Pfizer investors have had enough of the patent cliff already. The big pharma giant's loss of patent exclusivity on the world's former top-selling drug, cholesterol fighter Lipitor, has cost its drug revenues dearly. Pfizer's sales have fallen...
Bristol-Myers (BMY) Beats on Q2 Earnings, Maintains Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 4:00PM CDT
Bristol-Myers's (BMY) second quarter 2014 earnings of 46 cents per share beat the Zacks Consensus Estimate by 2 cents.
AmerisourceBergen Beats on Q3 Earnings & Revenues, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 3:45PM CDT
AmerisourceBergen Corp. (ABC) posted earnings of $1.01 per share in the third quarter of fiscal 2014 (ended Jun 30, 2014), which beat the Zacks Consensus Estimate of 92 cents.
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Midday Glance: Pharmaceuticals companies
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Thu Jul 24, 10:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Bristol 2Q net drops on lower drug sales, charges
AP - Thu Jul 24, 9:53AM CDT
NEW YORK (AP) — Bristol-Myers Squibb Co.'s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.
Michigan governor's campaign met with ambivalence
AP - Thu Jul 24, 9:14AM CDT
LANSING, Mich. (AP) — Michigan Gov. Rick Snyder has accomplished much of what he set out to do when he was elected four years ago. He's logged improvements in the state's economic health, presided over the creation of 250,000 private-sector jobs and confronted many of Detroit's worsening financial problems.
Eli Lilly Beats on Q2 Earnings & Revs, Maintains View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:05AM CDT
Although Eli Lilly's (LLY) results were better-than-expected, earnings and revenues declined from the year-ago quarter due to the genericization of Cymbalta and Evista.
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
What Will Puma Biotechnology Inc's $700 Million Man Do Next?
Brian Orelli, The Motley Fool - Motley Fool - Wed Jul 23, 6:21PM CDT
Alan Auerbach, CEO, president, and chairman of Puma Biotechnology , you just personally made over $700 million after your biotech suddenly soared 295% (more if you exercise all those warrants and options you have), what are you going to do now? ...
Why Do We Watch the Dow Jones So Closely When its Makeup Makes No Sense?
Alex Planes, The Motley Fool - Motley Fool - Wed Jul 23, 3:30PM CDT
The Dow Jones Industrial Average is a strange beast. With only 30 components, it can't possibly represent the scope of American stock markets as well as the broader S&P 500 . Yet not only does the Dow follow the S&P fairly closely in any...
Puma Biotechnology Stock Shoves It in Short Sellers' Faces
George Budwell, The Motley Fool - Motley Fool - Wed Jul 23, 3:01PM CDT
Biotech stocks are not for the faint of heart by any stretch of the imagination. Puma Biotechnology has repeatedly shown the investing world why this is the case, and today's 200% plus movement upward should drive this point home. PBYI ...
Why Puma Biotechnology Inc Stock More Than Tripled Today
Dan Carroll, The Motley Fool - Motley Fool - Wed Jul 23, 1:05PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Puma Biotechnology , a clinical-stage...
Puma Biotech Surges on Positive Results on Neratinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 12:41PM CDT
Shares of Puma Biotechnology, Inc. (PBYI) soared significantly after the company reported positive top-line results from the phase III trial on pipeline candidate, neratinib (PB272).